Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics
Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics Professional…
Lucid Diligence Brief: Halozyme × Skye Bioscience evaluating ENHANZE + nimacimab in obesity
Lucid Diligence Brief: Halozyme × Skye Bioscience evaluating ENHANZE +…
Lucid Diligence Brief: Zelgen × AbbVie option-to-license on alveltamig
Lucid Diligence Brief: Zelgen × AbbVie option-to-license on alveltamig…
Lucid Diligence Brief: Neuralink’s 2026 high-volume BCI plan
Lucid Diligence Brief: Neuralink’s 2026 high-volume BCI plan Professional…
Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics
Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics…
Lucid Diligence Brief: Rectify and Boehringer Ingelheim partnership in CKD
Lucid Diligence Brief: Rectify and Boehringer Ingelheim partnership in CKD…
Lucid Diligence Brief: Surv BioPharma ¥670 million in Series B for primary malignant bone tumors
Lucid Diligence Brief: Surv BioPharma ¥670 million in Series B for primary…
Lucid Diligence Brief: Gilead licenses Assembly Bio’s HSV helicase-primase programs
Lucid Diligence Brief: Gilead licenses Assembly Bio’s HSV helicase-primase…
Lucid Diligence Brief: Vyriad $25M Series B to take in-vivo CAR-T into clinic
Lucid Diligence Brief: Vyriad $25M Series B to take in-vivo CAR-T into clinic…
Lucid Diligence Brief: Sanofi moves to buy Dynavax for $2.2B
Lucid Diligence Brief: Sanofi moves to buy Dynavax for $2.2B Professional…
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal Professional…
Lucid Diligence Brief: BioMarin to acquire Amicus Therapeutics for $4.8B
Lucid Diligence Brief: BioMarin to acquire Amicus Therapeutics for $4.8B…